Biotech Specialty Pharma

BioDelivery Sciences International

801 Corporate Center Drive, Suite 210
Raleigh, NC 27607 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Drug delivery technologies with significant outlicenses as well as a proprietary pipeline.

Management Mark A. Sirgo, Pharm. D., President and Chief Executive Officer; Andrew L. Finn, Pharm.D., Executive Vice President of Product Development; James A. McNulty, CPA, Chief Financial Officer; Charles E. Dadswell, Esq., General Counsel; Albert J. Medwar, M.B.A., Vice President, Marketing

Click here for Financial Data
Keywords: drug delivery technologies, healthcare, BEMA technologies, bioral technologies, buprenorphine


Updated: Sept. 11, 2014


Biodelivery Sciences International is a specialty pharmaceutical company using its proprietary drug delivery technologies to develop new applications for proven therapeutics.......view more

Products / Services

Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer, was launched in October 2009. BioDelivery Sciences licensed the commercialization and distribution rights for......view more

Technology / Differentiation

BioDelivery Sciences International's drug delivery technologies include both BEMA and Bioral delivery technologies. The company, using these technologies, develops formulations of pharmaceuticals aime...view more

Market / Customers

BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseas......view more

Competitors / Substitutes / Alternatives

Cephalon Inc., ProStrakan., Gilead Sciences, Inc....view more


BDSI is applying its drug delivery technologies to improve the pharmacokinetics and bioavailability of currently-marketed prescription pharmaceutical products, with plans to outlicense select compound...view more


In October 2009, BDSI launched its first product, Onsolis (fentanyl buccal soluble film). Results from a Phase 2 study of BEMA Buprenorphine for pain were also completed and positive results announce...view more